Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up, Annals of Oncology, vol.20, pp.126-128, 2009. ,
Standards of care for treatment of recurrent glioblastoma-are we there yet?, Neuro-Oncology, vol.15, issue.1, pp.4-27, 2013. ,
Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo, Proceedings of the National Academy of Sciences of the United States of America, vol.91, issue.8, pp.3054-3057, 1994. ,
Emerging Cellular Therapies for Glioblastoma Multiforme, Cureus, vol.10, issue.3, p.2305, 2018. ,
Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells, Frontiers in Immunology, vol.9, p.824, 2018. ,
A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy, Journal of Immunology Research, p.326545, 2014. ,
Overview of cellular immunotherapy for patients with glioblastoma, Clinical and Developmental Immunology, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00532866
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy, The New England Journal of Medicine, vol.375, issue.26, pp.2561-2569, 2016. ,
Stereotaxic administrations of allogeneic human Vgamma9Vdelta2 T cells efficiently control the development of human glioblastoma brain tumors, Oncoimmunology, vol.5, issue.6, p.1168554, 2016. ,
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy, Brain, vol.135, pp.1042-1054, 2012. ,
IL-21 Increases the Reactivity of Allogeneic Human Vgamma9Vdelta2 T Cells Against Primary Glioblastoma Tumors, Journal of Immunotherapy, vol.41, issue.5, pp.224-231, 2018. ,
Effector memory alphabeta T lymphocytes can express FcgammaRIIIa and mediate antibody-dependent cellular cytotoxicity, The Journal of Immunology, vol.180, issue.8, pp.5327-5334, 2008. ,
Intracranial implantation with subsequent 3D in vivo bioluminescent imaging of murine gliomas, Journal of Visualized Experiments, issue.57, p.3403, 2011. ,
Treg depletion followed by intracerebral CpG-ODN injection induce brain tumor rejection, Journal of Neuroimmunology, vol.267, issue.1-2, pp.35-42, 2014. ,
, CAR T cell immunotherapy for human cancer. Science, vol.359, issue.6382, pp.1361-1365, 2018.
Adoptive T cell therapy: An overview of obstacles and opportunities, Cancer, vol.123, issue.S11, pp.2154-2162, 2017. ,
Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma, Neuro-Oncology, vol.11, issue.4, pp.357-367, 2009. ,
The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation, Cancer Immunology, Immunotherapy, vol.64, issue.5, pp.551-562, 2015. ,
Innate and adaptive immune responses of the central nervous system, Critical Reviews in Immunology, vol.26, issue.2, pp.149-188, 2006. ,
Structural and functional features of central nervous system lymphatic vessels, Nature, vol.523, issue.7560, pp.337-341, 2015. ,
Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study, Cancer, vol.86, issue.2, pp.325-330, 1999. ,
Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma, Cancer, vol.100, issue.2, pp.405-410, 2004. ,
Large scale expansion of gamma 9 delta 2 T lymphocytes: Innacell gamma delta cell therapy product, Journal of Immunological Methods, vol.326, issue.1-2, pp.63-75, 2007. ,
Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma, Cancer Immunology, Immunotherapy, vol.57, issue.11, pp.1599-1609, 2008. ,
Identification of human brain tumour initiating cells, Nature, vol.432, issue.7015, pp.396-401, 2004. ,